GSK appoints six directors for consumer healthcare business Haleon before it’s spun out later this year
GlaxoSmithKline (GSK) has unveiled six appointments to the board of Haleon, the consumer healthcare business that will be spun out later this year.
Haleon, which hired ex-Tesco boss Sir Dave Lewis as chairman in December, recruited two of GSK’s non-executive directors – Vindi Banga and Dame Vivienne Cox – as well as three new external hires.
These include Tracy Clarke, a former chief executive at banking giant Standard Chartered, and Deirdre Mahlan, the previous head of North American operations at Guinness owner Diageo.
Split: GlaxoSmithKline has appointed six new directors of its consumer arm Haleon last December
Also joining is John Young, of US rival Pfizer, which owns around a third of the consumer healthcare business through a joint venture.
Tobias Hestler, the designated chief financial officer of Haleon, will be made an executive director, to join boss Brian McNamara.
Lewis said the appointments will bring ‘considerable board experience’ and the drugs giant plans to add three more directors.
Haleon is due to separate from GSK in July, taking control of GSK’s large portfolio of well-known healthcare brands such as Sensodyne toothpaste.
It will list in London and is expected to fetch a value of around £45billion.